169 related articles for article (PubMed ID: 12476309)
1. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
Ren R
Oncogene; 2002 Dec; 21(56):8629-42. PubMed ID: 12476309
[TBL] [Abstract][Full Text] [Related]
2. The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
Wertheim JA; Miller JP; Xu L; He Y; Pear WS
Oncogene; 2002 Dec; 21(56):8612-28. PubMed ID: 12476308
[TBL] [Abstract][Full Text] [Related]
3. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
4. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
5. CML mouse model in translational research.
Peng C; Li S
Methods Mol Biol; 2010; 602():253-66. PubMed ID: 20012403
[TBL] [Abstract][Full Text] [Related]
6. Animal models of chronic myelogenous leukemia.
Ilaria RL
Hematol Oncol Clin North Am; 2004 Jun; 18(3):525-43, vii. PubMed ID: 15271391
[TBL] [Abstract][Full Text] [Related]
7. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of transformation by the BCR-ABL oncogene.
Sattler M; Griffin JD
Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Ren R
Nat Rev Cancer; 2005 Mar; 5(3):172-83. PubMed ID: 15719031
[TBL] [Abstract][Full Text] [Related]
11. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
Kabarowski JH; Witte ON
Stem Cells; 2000; 18(6):399-408. PubMed ID: 11072027
[TBL] [Abstract][Full Text] [Related]
12. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
[TBL] [Abstract][Full Text] [Related]
13. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
14. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
15. Studying the pathogenesis of BCR-ABL+ leukemia in mice.
Van Etten RA
Oncogene; 2002 Dec; 21(56):8643-51. PubMed ID: 12476310
[TBL] [Abstract][Full Text] [Related]
16. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
Skórski T
Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
19. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
20. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Melo JV; Deininger MW
Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]